Hosted on MSN5h
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug NipocalimabHOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a ...
The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback